Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Background: Success of T cell immunotherapy hinges on the tumor microenvironment (TME), and abnormal tumor vasculature is a hallmark of most solid tumors and associated with immune evasion. The efficacy of T cell engaging bispecific antibody (BsAb) treatment relies on the successful trafficking and cytolytic activity of T cells in solid tumors. Normalization of tumor vasculature using vascular endothelial growth factor (VEGF) blockades could improve efficacy of BsAb-based T cell immunotherapy. Methods: Anti-human VEGF (bevacizumab, BVZ) or anti-mouse VEGFR2 antibody (DC101) was used as VEGF blockade, and ex vivo armed T cells (EATs) carrying anti-GD2, anti-HER2, or anti-glypican3 (GPC3) IgG-(L)-scFv platformed BsAb were used. BsAb-driven intratumoral T cell infiltration and in vivo antitumor response were evaluated using cancer cell line-derived xenografts (CDXs) or patient-derived xenografts (PDXs) carried out in BALB-Rag2 -/-IL-2R-γc-KO (BRG) mice. VEGF expression on human cancer cell lines was analyzed by flow cytometry, and VEGF levels in mouse serum were measured using VEGF Quantikine ELISA Kit. Tumor infiltrating lymphocytes (TILs) were evaluated using flow cytometry and by bioluminescence; both TILs and tumor vasculature were studied using immunohistochemistry. Results: VEGF expression on cancer cell lines increased with seeding density in vitro. BVZ significantly reduced serum VEGF levels in mice. BVZ or DC101 increased high endothelial venules (HEVs) in the TME and substantially enhanced (2.1–8.1 fold) BsAb-driven T cell infiltration into neuroblastoma and osteosarcoma xenografts, which was preferential for CD8(+) TILs versus CD4(+) TILs, leading to superior antitumor effects in multiple CDX and PDX tumor models without added toxicities. Conclusions: VEGF blockade using specific antibodies against VEGF or VEGFR2 increased HEVs in the TME and cytotoxic CD8(+) TILs, significantly improving the therapeutic efficacy of EAT strategies in preclinical models, supporting the clinical investigation of VEGF blockades to further enhance BsAb-based T cell immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“VEGF blockade enhanced the infiltration of tumor-antigens (GD2/HER2/GPC3) armed T cells into tumor microenvironment and increased CD8+ T cells survival and dispersion [160].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [160]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
The role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Homing and cellular traffic in lymph nodes
von Andrian, U. H., & Mempel, T. R. (2003) · Nature Reviews Immunology · doi:10.1038/nri1222 · Cited by 1,281
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Goel, H. L., & Mercurio, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3627 · Cited by 1,253
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035
The hypoxic tumour microenvironment
Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G., & Amelio, I. (2018) · Oncogenesis · doi:10.1038/s41389-017-0011-9 · Cited by 1,019
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820
Ligands for L-Selectin: Homing, Inflammation, and Beyond
Rosen, S. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.090501.080131 · Cited by 790
HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes
Girard, J.-P., Moussion, C., & Förster, R. (2012) · Nature Reviews Immunology · doi:10.1038/nri3298 · Cited by 713
Wallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713
Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair
Hu, K., & Olsen, B. R. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82585 · Cited by 668
Doedens, A. L., Stockmann, C., Rubinstein, M. P., Liao, D., Zhang, N., DeNardo, D. G., Coussens, L. M., Karin, M., Goldrath, A. W., & Johnson, R. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1439 · Cited by 652
Targeting VEGF/VEGFR to modulate antitumor immunity
Yang, J., Yan, J., & Liu, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00978 · Cited by 646
Co-evolution of tumor cells and their microenvironment
Polyak, K., Haviv, I., & Campbell, I. G. (2009) · Trends in Genetics · doi:10.1016/j.tig.2008.10.012 · Cited by 628
Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2)
Gille, H., Kowalski, J., Li, B., LeCouter, J., Moffat, B., Zioncheck, T. F., Pelletier, N., & Ferrara, N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m002016200 · Cited by 620
Basic and Therapeutic Aspects of Angiogenesis Updated
Eelen, G., Treps, L., Li, X., & Carmeliet, P. (2020) · Circulation Research · doi:10.1161/circresaha.120.316851 · Cited by 568
High endothelial venules (HEVs): specialized endothelium for lymphocyte migration
Girard, J.-P., & Springer, T. A. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80023-9 · Cited by 552
Martinet, L., Garrido, I., Filleron, T., Le Guellec, S., Bellard, E., Fournie, J.-J., Rochaix, P., & Girard, J.-P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0431 · Cited by 516
Meyer, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.2.363 · Cited by 509
Muller, Y. A., Li, B., Christinger, H. W., Wells, J. A., Cunningham, B. C., & de Vos, A. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7192 · Cited by 452
Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H. W., McKay, P., de Vos, A. M., & Lowman, H. B. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3192 · Cited by 448
Liang, W.-C., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H.-P., Ferrara, N., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508199200 · Cited by 346
Asrir, A., Tardiveau, C., Coudert, J., Laffont, R., Blanchard, L., Bellard, E., Veerman, K., Bettini, S., Lafouresse, F., Vina, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.002 · Cited by 257
High endothelial venules (HEVs) in immunity, inflammation and cancer
Blanchard, L., & Girard, J.-P. (2021) · Angiogenesis · doi:10.1007/s10456-021-09792-8 · Cited by 207
Endothelial-to-Mesenchymal Transition in Cancer
Clere, N., Renault, S., & Corre, I. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00747 · Cited by 199
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer
Chatterjee, S., Heukamp, L. C., Siobal, M., Schöttle, J., Wieczorek, C., Peifer, M., Frasca, D., Koker, M., König, K., Meder, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65385 · Cited by 195
Interaction between Bevacizumab and Murine VEGF-A: A Reassessment
Yu, L., Wu, X., Cheng, Z., Lee, C. V., LeCouter, J., Campa, C., Fuh, G., Lowman, H., & Ferrara, N. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1175 · Cited by 180
Bocci, G., Man, S., Green, S. K., Francia, G., Ebos, J. M. L., du Manoir, J. M., Weinerman, A., Emmenegger, U., Ma, L., Thorpe, P., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0401 · Cited by 162
Falcón, B. L., Chintharlapalli, S. R., Uhlik, M. T., & Pytowski, B. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.001 · Cited by 150
Bevacizumab Attenuates VEGF-Induced Angiogenesis and Vascular Malformations in the Adult Mouse Brain
Walker, E. J., Su, H., Shen, F., Degos, V., Amend, G., Jun, K., & Young, W. L. (2012) · Stroke · doi:10.1161/strokeaha.111.647982 · Cited by 145
VEGFR2 is selectively expressed by FOXP3high CD4+ Treg
Suzuki, H., Onishi, H., Wada, J., Yamasaki, A., Tanaka, H., Nakano, K., Morisaki, T., & Katano, M. (2010) · European Journal of Immunology · doi:10.1002/eji.200939887 · Cited by 124
High Endothelial Venules: A Vascular Perspective on Tertiary Lymphoid Structures in Cancer
Vella, G., Guelfi, S., & Bergers, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.736670 · Cited by 121
Ren, S., Xiong, X., You, H., Shen, J., & Zhou, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689132 · Cited by 114
Polymerase chain reaction (PCR) techniques for site-directed mutagenesis
Reikofski, J., & Tao, B. Y. (1992) · Biotechnology Advances · doi:10.1016/0734-9750(92)91451-j · Cited by 112
A modular IgG-scFv bispecific antibody topology
Orcutt, K. D., Ackerman, M. E., Cieslewicz, M., Quiroz, E., Slusarczyk, A. L., Frangioni, J. V., & Wittrup, K. D. (2010) · Protein Engineering, Design and Selection · doi:10.1093/protein/gzp077 · Cited by 100
Understanding high endothelial venules: Lessons for cancer immunology
Ager, A., & May, M. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008791 · Cited by 99
Whatcott, C. J., Han, H., & Von Hoff, D. D. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000140 · Cited by 97
Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody
Xu, H., Cheng, M., Guo, H., Chen, Y., Huse, M., & Cheung, N.-K. V. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0230-t · Cited by 92
Self-citationGD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Park, J. A., & Cheung, N.-K. V. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01012-y · Cited by 88
Self-citationOvercoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
Lopez-Albaitero, A., Xu, H., Guo, H., Wang, L., Wu, Z., Tran, H., Chandarlapaty, S., Scaltriti, M., Janjigian, Y., de Stanchina, E., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1267891 · Cited by 80
Self-citationImmune Effects of Bevacizumab: Killing Two Birds with One Stone
Elamin, Y. Y., Rafee, S., Toomey, S., & Hennessy, B. T. (2014) · Cancer Microenvironment · doi:10.1007/s12307-014-0160-8 · Cited by 68
Neuchrist, C., Erović, B. M., Handisurya, A., Steiner, G., Rockwell, P., Gedlicka, C., & Burian, M. (2001) · The Laryngoscope · doi:10.1097/00005537-200110000-00031 · Cited by 64
Neogenesis and development of the high endothelial venules that mediate lymphocyte trafficking
Hayasaka, H., Taniguchi, K., Fukai, S., & Miyasaka, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01687.x · Cited by 61
The vascular landscape of human cancer
Kahn, B. M., Lucas, A., Alur, R. G., Wengyn, M. D., Schwartz, G. W., Li, J., Sun, K., Maurer, H. C., Olive, K. P., Faryabi, R. B., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci136655 · Cited by 54
Park, J. A., Wang, L., & Cheung, N. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01156-5 · Cited by 52
Self-citationPark, J. A., Santich, B. H., Xu, H., Lum, L. G., & Cheung, N. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002222 · Cited by 48
Self-citationKing, C. R., & Hristova, K. A. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007737 · Cited by 42
Mujagić, E., Giannì-Barrera, R., Trani, M., Patel, A. M., Gürke, L., Heberer, M., Wolff, T. E., & Banfi, A. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.197 · Cited by 30
Cited by
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“In addition to ICIs, Park et al. conducted the preclinical study demonstrating that VEGF blockade enhanced the infiltration of tumor-antigens (GD2/HER2/GPC3) armed T cells into tumor microenvironment and increased CD8 + T cells survival and dispersion [160].”
BackgroundZheng, S., Wang, W., Shen, L., Yao, Y., Xia, W., & Ni, C. (2024) · Experimental Hematology & Oncology · doi:10.1186/s40164-024-00543-1 · Cited by 163
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 183
Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis
Nirala, B. K., Yamamichi, T., Petrescu, D. I., Shafin, T. N., & Yustein, J. T. (2023) · Cancers · doi:10.3390/cancers15205108 · Cited by 58
Promise and Challenges of T Cell Immunotherapy for Osteosarcoma
Park, J. A., & Cheung, N. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512520 · Cited by 51
Self-citation
Metadata
- Authors
- Park, J. A., Espinosa-Cotton, M., Guo, H.-F., Monette, S., & Cheung, N.-K. V.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
- Corresponding author
- Cheung, Nai-Kong V
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2023-03
- Volume
- 11
- Issue
- 3
- Pages
- e006680
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC10069597
- OpenAlex
- W4361295500
- Cited by
- 46
- References
- 59
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 14 · 2023: 5
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Kids Walk for Kids with Cancer (N/A)
- NCI Cancer Center Support Grant (P30 CA008748)
- Korea Health Technology R&D Project (HI12C1488)
- Enid A. Haupt Endowed Chair (N/A)
- Robert Steel Foundation (N/A)
- Inha University Research Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor vasculature normalization, VEGF inhibition, T-cell bispecific antibodies, ex vivo T cell engineering, tumor microenvironment, VEGFR2, bevacizumab, DC101, high endothelial venules, T cell infiltration, tumor-infiltrating lymphocytes, CD8+ T cells, neuroblastoma, osteosarcoma, GD2, HER2
- MeSH terms
- Animals, Humans, Immunotherapy, T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Antibodies, Bispecific, Vascular Endothelial Growth Factor A, Mice, Glypicans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.